Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 7/20 | 0.58 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.53 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.53 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.53 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.53 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | S100B | P04271 | 1/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | AOC1 | P19801 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548439 | 0.96 | PRSS1 (0.60) | TMPRSS2PRSS1PRMT1F2ST14 | |
| SCHEMBL20332718 | 0.94 | TMPRSS2 (0.55) | TMPRSS2PRSS1PRMT1F2ST14 | |
| Pentamidine Dao SCHEMBL548448 | 0.94 | PRMT1 (0.61) | TMPRSS2PRSS1PRMT1F2ST14 | |
| SCHEMBL23588050 | 0.91 | TMPRSS2 (0.51) | TMPRSS2PRSS1PRMT1F2ST14 | |
| SCHEMBL6407420 | 0.91 | MMP1 (0.56) | TMPRSS2PRSS1CYP2D6MMP1 | |
| SCHEMBL409427 | 0.89 | NR1I2 (0.53) | TMPRSS2PRSS1PRMT1F2ST14 | |
| SCHEMBL8718224 | 0.88 | TP53 (0.57) | PRSS1MMP1 | |
| SCHEMBL3275310 | 0.87 | PLK1 (0.56) | TMPRSS2PRSS1CYP2D6L3MBTL1MMP1 | |
| SCHEMBL6510086 | 0.86 | TP53 (0.59) | TMPRSS2PRMT1F2ST14PLAU | |
| SCHEMBL5543953 | 0.86 | PRMT1 (0.53) | TMPRSS2PRSS1PRMT1F2ST14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| EP-0861071-B1 | BENZAMIDOXIME PRODRUGS AND USE THEREOF FOR TREATING PNEUMONIA | UNIV NORTH CAROLINA (US) | 2005-05-11 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| US-6025398-A | Benzamidoxime prodrugs as antipneumocystic agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2000-02-15 | — | — | US | disclosed |
| US-5843980-A | Benzamidoxime prodrugs as antipneumocystic agents | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0861071-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5723495-A | TREATMENT OF PNEUMONIA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1998-03-03 | — | — | US | disclosed |
| WO-1997017949-A1 | BENZAMIDOXIME PRODRUGS AS ANTIPNEUMOCYSTIC AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | TP53, IDH3A, IDH2 | TMPRSS2 3181/4885PRSS1 3740/4885PRMT1 26/4885 |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | TMPRSS2 2714/4885PRSS1 3168/4885PRMT1 2728/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | TMPRSS2 1369/4885PRSS1 2212/4885PRMT1 2584/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | TMPRSS2 2079/4885PRSS1 1458/4885PRMT1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.